Cellsource Co Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
Metrics to compare | 4880 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4880PeersSector | |
|---|---|---|---|---|
P/E Ratio | 772.1x | −4.0x | −0.5x | |
PEG Ratio | - | −0.39 | 0.00 | |
Price/Book | 1.3x | 1.6x | 2.6x | |
Price / LTM Sales | 2.1x | 1.8x | 3.2x | |
Upside (Analyst Target) | 133.4% | 23.9% | 49.3% | |
Fair Value Upside | Unlock | −9.3% | 6.3% | Unlock |